Voyager Therapeutics (VYGR) Projected to Post Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Trading Down 2.8 %

Shares of NASDAQ:VYGR opened at $4.10 on Tuesday. Voyager Therapeutics has a 12-month low of $4.00 and a 12-month high of $10.66. The business’s fifty day simple moving average is $5.32 and its 200-day simple moving average is $6.07. The company has a market capitalization of $223.97 million, a PE ratio of 5.77 and a beta of 0.91.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 10,778 shares of company stock worth $58,548 in the last ninety days. 4.53% of the stock is owned by insiders.

Analyst Ratings Changes

VYGR has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, January 27th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.